Mainz Biomed N.V., a molecular genetics diagnostic company focused on early cancer detection, announced that its pancreatic cancer project will receive public funding from the Investitions- und ...

Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future ...

Mainz Biomed's product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of ...

Issuer: Mainz BioMed N.V. / Key word (s): Miscellaneous 25.06.2025 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed Secures Public Funding to ...

BERKELEY, US and MAINZ, Germany – June 25, 2025 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of ...

Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future ...

BERKELEY, US and MAINZ, Germany – June 25, 2025 - Mainz Biomed N.V. MYNZ ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer ...

Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of ...

Get today's Mainz Biomed BV stock news. We cover the latest Mainz Biomed BV headlines and breaking news impacting Mainz Biomed BV stock performance.